Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18130922 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL9442918 | 1.00 | — | — | |
| SCHEMBL42799 | 0.97 | — | — | |
| SCHEMBL2705159 | 0.97 | — | — | |
| SCHEMBL82804 | 0.97 | — | — | |
| Alcohol SCHEMBL8666140 | 0.95 | ALDH1A1 (0.48) | — | |
| Alcohol SCHEMBL8669974 | 0.95 | ALDH1A1 (0.48) | — | |
| Propanol SCHEMBL9304318 | 0.92 | ALDH1A1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL9485798 | 0.92 | CYP2D6 (0.54) | — | |
| Hydrochloric Acid SCHEMBL7066824 | 0.90 | CYP2D6 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-115362155-A | Arylamine derivatives, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180273553-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10011616-B2 | Boron-containing small molecules as antiprotozoal1 agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-07-03 | — | — | US | disclosed |
| CN-101084216-B | Inhibitors for the soluble epoxide hydrolase | UNIV CALIFORNIA | 2011-09-14 | — | — | CN | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| CN-101084216-A | Inhibitors for the soluble epoxide hydrolase | UNIV CALIFORNIA (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1814875-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | The Regents of the University of California (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060270609-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-30 | — | — | US | disclosed |
| WO-2006045119-A9 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006045119-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-27 | — | — | WO | disclosed |
| US-4244967-A | ANTIIFLAMMATORY AND ANTIRHEUMATIC PROPERTIES | BOEHRINGER INGELHEIM GMBH (DE) | 1981-01-13 | — | — | US | disclosed |